{
    "organizations": [],
    "uuid": "1fcd7042ae5c313982f6c396d586c621fc858500",
    "author": "",
    "url": "https://www.reuters.com/article/brief-sarepta-therapeutics-provides-fy-2/brief-sarepta-therapeutics-provides-fy-2018-rev-forecast-for-exondys-51-idUSASB0C07Y",
    "ord_in_thread": 0,
    "title": "BRIEF-Sarepta Therapeutics Provides FY 2018 Rev Forecast For Exondys 51",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 8, 2018 / 6:50 PM / Updated 21 minutes ago BRIEF-Sarepta Therapeutics Provides FY 2018 Rev Forecast For Exondys 51 Reuters Staff 1 Min Read \nJan 8 (Reuters) - Sarepta Therapeutics Inc: \n* SAREPTA THERAPEUTICS PRE-ANNOUNCES FOURTH QUARTER 2017 REVENUE AND PROVIDES FULL-YEAR 2018 REVENUE GUIDANCE FOR EXONDYS 51® (ETEPLIRSEN), REPRESENTING APPROXIMATELY 100 PERCENT YEAR-OVER-YEAR GROWTH \n* Q4 REVENUE $57.3 MILLION VERSUS I/B/E/S VIEW $55.8 MILLION * SEES FY 2018 REVENUE $295 MILLION TO $305 MILLION \n* SAYS FULL-YEAR 2018 EXONDYS 51 REVENUE GUIDANCE OF $295 - $305 MILLION \n* SAYS ‍FULL-YEAR 2017 EXONDYS 51 UNAUDITED REVENUE OF $154.6 MILLION​ Source text for Eikon: Further company coverage:",
    "published": "2018-01-08T20:49:00.000+02:00",
    "crawled": "2018-01-08T21:16:50.004+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "updated",
        "minute",
        "ago",
        "therapeutic",
        "provides",
        "fy",
        "rev",
        "forecast",
        "exondys",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "sarepta",
        "therapeutic",
        "inc",
        "sarepta",
        "therapeutic",
        "fourth",
        "quarter",
        "revenue",
        "provides",
        "revenue",
        "guidance",
        "exondys",
        "eteplirsen",
        "representing",
        "approximately",
        "percent",
        "growth",
        "q4",
        "revenue",
        "million",
        "versus",
        "view",
        "million",
        "see",
        "fy",
        "revenue",
        "million",
        "million",
        "say",
        "exondys",
        "revenue",
        "guidance",
        "million",
        "say",
        "exondys",
        "unaudited",
        "revenue",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}